Altered inotropic responsiveness and gene expression of hypertrophied myocardium with captopril

W W Brooks1, O H Bing, M O Boluyt

  • 1Cardiovascular Division, Boston Veterans Affairs Medical Center , Boston, MA 02130, USA.

Insights

Captopril treatment improved heart function in hypertensive rats by normalizing calcium handling and increasing key proteins. This restored the heart's responsiveness to beta-adrenergic stimulation, crucial for treating heart failure.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Left ventricular (LV) hypertrophy and failure typically impair inotropic responsiveness to beta-adrenergic stimulation.
  • Understanding how angiotensin-converting enzyme inhibitor therapy affects this responsiveness is crucial for managing heart conditions.

Purpose of the Study:

  • To investigate the effects of long-term captopril treatment on cardiac gene expression, LV muscle contraction, and intracellular calcium transients in spontaneously hypertensive rats (SHR) with pressure overload.

Main Methods:

  • Studied LV papillary muscles from untreated SHR, Wistar-Kyoto rats (WKY), and captopril-treated SHR (CAP(Rx)) at 24 months of age or upon heart failure development.
  • Assessed cardiac gene expression (alpha-myosin heavy chain [MHC]), protein levels, Na+/Ca(2+) exchanger mRNA, and intracellular calcium (Ca(2+)) transients using aequorin.
  • Measured mechanical contraction, including active stress development and contractile duration, with and without isoproterenol stimulation.

Main Results:

  • Untreated SHR showed decreased alpha-MHC, prolonged Ca(2+) transients, increased Na+/Ca(2+) exchanger mRNA, and depressed muscle function compared to WKY.
  • Isoproterenol further impaired contractility in untreated SHR.
  • CAP(Rx) SHR exhibited increased alpha-MHC, normalized Ca(2+) transients, downregulated Na+/Ca(2+) exchanger, and enhanced contractile function with isoproterenol stimulation.

Conclusions:

  • Captopril treatment in SHR normalized LV inotropic responsiveness to beta-adrenergic stimulation.
  • This restoration is linked to normalized Na+/Ca(2+) exchanger mRNA, increased V(1) myosin isozyme, and improved contraction speed.
  • Captopril appears to modulate cardiac gene expression transcriptionally, offering a therapeutic strategy for heart failure.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...